Sidoti Brokers Decrease Earnings Estimates for USNA

USANA Health Sciences, Inc. (NYSE:USNA) – Equities research analysts at Sidoti decreased their Q3 2026 earnings estimates for shares of USANA Health Sciences in a research note issued on Wednesday, August 5th. Sidoti analyst A. Lebiedzinski now forecasts that the company will post earnings of $0.09 per share for the quarter, down from their previous estimate of $0.43. The consensus estimate for USANA Health Sciences’ current full-year earnings is $0.76 per share. Sidoti also issued estimates for USANA Health Sciences’ Q4 2026 earnings at $0.11 EPS, FY2026 earnings at $0.76 EPS, Q1 2027 earnings at $0.31 EPS, Q2 2027 earnings at $0.43 EPS, Q3 2027 earnings at $0.47 EPS, Q4 2027 earnings at $0.50 EPS and FY2027 earnings at $1.77 EPS.

A number of other brokerages have also issued reports on USNA. Weiss Ratings restated a “sell (d)” rating on shares of USANA Health Sciences in a research note on Wednesday, June 24th. Zacks Research lowered USANA Health Sciences from a “strong-buy” rating to a “hold” rating in a report on Wednesday, April 22nd. Finally, Wall Street Zen upgraded USANA Health Sciences from a “hold” rating to a “buy” rating in a research note on Saturday, June 20th. One equities research analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, USANA Health Sciences has an average rating of “Reduce”.

USANA Health Sciences Price Performance

Shares of USNA opened at $14.87 on Friday. The company’s fifty day moving average price is $20.47 and its 200-day moving average price is $19.69. USANA Health Sciences has a 1-year low of $14.35 and a 1-year high of $32.32. The firm has a market capitalization of $274.44 million, a PE ratio of -12.29, a price-to-earnings-growth ratio of 1.64 and a beta of 0.73.

USANA Health Sciences (NYSE:USNA) last issued its quarterly earnings results on Tuesday, August 4th. The company reported ($0.07) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.43 by ($0.50). The company had revenue of $223.27 million for the quarter, compared to analyst estimates of $235.00 million. USANA Health Sciences had a negative net margin of 2.43% and a positive return on equity of 3.41%. USANA Health Sciences has set its FY 2026 guidance at 0.760-0.760 EPS.

Hedge Funds Weigh In On USANA Health Sciences

Several large investors have recently made changes to their positions in USNA. Bank of New York Mellon Corp purchased a new stake in USANA Health Sciences during the second quarter worth $1,105,000. State of Wyoming purchased a new position in USANA Health Sciences in the second quarter valued at $242,000. GSA Capital Partners LLP acquired a new position in shares of USANA Health Sciences in the second quarter worth about $250,000. Versant Capital Management Inc raised its position in shares of USANA Health Sciences by 1,472.3% in the second quarter. Versant Capital Management Inc now owns 1,588 shares of the company’s stock worth $34,000 after acquiring an additional 1,487 shares during the period. Finally, Empowered Funds LLC boosted its stake in shares of USANA Health Sciences by 9.7% during the 1st quarter. Empowered Funds LLC now owns 66,293 shares of the company’s stock worth $1,158,000 after acquiring an additional 5,856 shares in the last quarter. 54.25% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at USANA Health Sciences

In related news, insider Brent Neidig sold 5,002 shares of the firm’s stock in a transaction dated Tuesday, June 16th. The stock was sold at an average price of $19.45, for a total transaction of $97,288.90. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director John Turman Fleming sold 2,450 shares of the business’s stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $17.93, for a total value of $43,928.50. Following the completion of the transaction, the director directly owned 4,230 shares of the company’s stock, valued at $75,843.90. The trade was a 36.68% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 13,869 shares of company stock worth $261,441 over the last quarter. 0.82% of the stock is currently owned by insiders.

About USANA Health Sciences

USANA Health Sciences, Inc is a Utah‐based company that develops, manufactures and distributes nutritional supplements and personal care products through a network of independent distributors. Founded in 1992 by Dr. Myron Wentz, the company’s portfolio includes vitamins, minerals, dietary supplements, weight‐management products and skin‐care formulations. USANA’s products are formulated in its own laboratories to meet pharmaceutical‐grade standards, and the company has invested heavily in research and development and quality control to support its offerings.

Operating primarily through a direct selling model, USANA serves markets in North America, Asia Pacific, Europe and Latin America.